Does the media refer more to KOD or CYTK?

In the previous week, Cytokinetics had 19 more articles in the media than Kodiak Sciences. MarketBeat recorded 23 mentions for Cytokinetics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Cytokinetics' score of 0.79 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or KOD?

In the previous week, Krystal Biotech had 16 more articles in the media than Kodiak Sciences. MarketBeat recorded 20 mentions for Krystal Biotech and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Krystal Biotech's score of 1.17 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 13 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer KOD or RDY?

Kodiak Sciences presently has a consensus target price of $42.14, suggesting a potential upside of 1.35%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Kodiak Sciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor KOD or RDY?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Dr. Reddy's Laboratories' score of 0.69 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, KOD or NUVL?

Nuvalent is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is KOD or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Nuvalent N/A -40.11% -35.43%

Does the media refer more to KOD or NUVL?

In the previous week, Kodiak Sciences had 3 more articles in the media than Nuvalent. MarketBeat recorded 4 mentions for Kodiak Sciences and 1 mentions for Nuvalent. Kodiak Sciences' average media sentiment score of 1.46 beat Nuvalent's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KOD or KYMR?

In the previous week, Kymera Therapeutics had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 10 mentions for Kymera Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Kymera Therapeutics' score of 0.75 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kodiak Sciences (KOD) Competitors

$41.58 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$41.22 -0.36 (-0.86%)

As of 07/31/2026 07:58 PM Eastern

Compare

KOD vs. CYTK, KRYS, RDY, NUVL, and KYMR

Should you buy Kodiak Sciences stock or one of its competitors? MarketBeat compares Kodiak Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kodiak Sciences include Cytokinetics (CYTK), Krystal Biotech (KRYS), Dr. Reddy's Laboratories (RDY), Nuvalent (NUVL), and Kymera Therapeutics (KYMR).

How does Kodiak Sciences compare to Cytokinetics?

Kodiak Sciences (NASDAQ:KOD) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Kodiak Sciences has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A

In the previous week, Cytokinetics had 19 more articles in the media than Kodiak Sciences. MarketBeat recorded 23 mentions for Cytokinetics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Cytokinetics' score of 0.79 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Cytokinetics	-784.02%	N/A	-52.86%

89.1% of Kodiak Sciences shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kodiak Sciences currently has a consensus price target of $42.14, indicating a potential upside of 1.35%. Cytokinetics has a consensus price target of $99.90, indicating a potential upside of 29.52%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Kodiak Sciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Summary

Kodiak Sciences and Cytokinetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Krystal Biotech has a net margin of 53.92% compared to Kodiak Sciences' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Kodiak Sciences	N/A	-253.85%	-81.48%

Krystal Biotech has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

Krystal Biotech presently has a consensus price target of $360.67, indicating a potential upside of 5.73%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential upside of 1.35%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Krystal Biotech had 16 more articles in the media than Kodiak Sciences. MarketBeat recorded 20 mentions for Krystal Biotech and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Krystal Biotech's score of 1.17 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	13 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Kodiak Sciences on 11 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Dr. Reddy's Laboratories?

Kodiak Sciences (NASDAQ:KOD) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Kodiak Sciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Dr. Reddy's Laboratories	$3.58B	2.76	$456M	$0.44	26.92

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Dr. Reddy's Laboratories' score of 0.69 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences presently has a consensus target price of $42.14, suggesting a potential upside of 1.35%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Kodiak Sciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Kodiak Sciences' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Summary

Dr. Reddy's Laboratories beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Nuvalent?

Kodiak Sciences (NASDAQ:KOD) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Kodiak Sciences had 3 more articles in the media than Nuvalent. MarketBeat recorded 4 mentions for Kodiak Sciences and 1 mentions for Nuvalent. Kodiak Sciences' average media sentiment score of 1.46 beat Nuvalent's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kodiak Sciences has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Nuvalent's return on equity of -40.11% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Nuvalent	N/A	-40.11%	-35.43%

Kodiak Sciences presently has a consensus target price of $42.14, suggesting a potential upside of 1.35%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Given Nuvalent's higher probable upside, analysts plainly believe Nuvalent is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Nuvalent is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Summary

Kodiak Sciences beats Nuvalent on 9 of the 13 factors compared between the two stocks.

How does Kodiak Sciences compare to Kymera Therapeutics?

Kodiak Sciences (NASDAQ:KOD) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Kymera Therapeutics had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 10 mentions for Kymera Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.46 beat Kymera Therapeutics' score of 0.75 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences currently has a consensus price target of $42.14, suggesting a potential upside of 1.35%. Kymera Therapeutics has a consensus price target of $124.48, suggesting a potential upside of 20.39%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Kodiak Sciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

89.1% of Kodiak Sciences shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kodiak Sciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Kodiak Sciences has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Kymera Therapeutics	$51.48M	165.23	-$311.35M	-$3.57	N/A

Summary

Kymera Therapeutics beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOD vs. The Competition

Export

Metric	Kodiak Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.60B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-9.97	7.38	282.28	24.66
Price / Sales	N/A	1,199.83	563.21	75.35
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	14.00	16.96	10.96	6.07
Net Income	-$229.97M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-0.79%	-1.80%	-0.63%	-0.44%
1 Month Performance	7.89%	-8.44%	-5.23%	-4.81%
1 Year Performance	525.26%	48.63%	62.07%	18.61%

Kodiak Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOD Kodiak Sciences	1.2871 of 5 stars	$41.58 flat	$42.14 +1.4%	+525.3%	$2.60B	N/A	N/A	90	News Coverage Positive News Gap Up
CYTK Cytokinetics	3.4909 of 5 stars	$80.62 -0.1%	$99.90 +23.9%	+110.2%	$10.05B	$105.82M	N/A	250	Positive News Upcoming Earnings
KRYS Krystal Biotech	3.2734 of 5 stars	$351.82 +5.0%	$360.67 +2.5%	+117.3%	$9.88B	$389.13M	47.03	210	News Coverage Positive News Earnings Report Gap Up
RDY Dr. Reddy's Laboratories	2.5423 of 5 stars	$11.79 0.0%	N/A	-15.1%	$9.84B	$3.58B	26.78	27,527
NUVL Nuvalent	1.6794 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KOD) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kodiak Sciences (KOD) Competitors

KOD vs. CYTK, KRYS, RDY, NUVL, and KYMR

How does Kodiak Sciences compare to Cytokinetics?

Summary

How does Kodiak Sciences compare to Krystal Biotech?

Summary

How does Kodiak Sciences compare to Dr. Reddy's Laboratories?

Summary

How does Kodiak Sciences compare to Nuvalent?

Summary

How does Kodiak Sciences compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kodiak Sciences (KOD) Competitors

KOD vs. CYTK, KRYS, RDY, NUVL, and KYMR

How does Kodiak Sciences compare to Cytokinetics?

Which has preferable earnings and valuation, KOD or CYTK?

Does the media refer more to KOD or CYTK?

Is KOD or CYTK more profitable?

Do insiders & institutionals have more ownership in KOD or CYTK?

Do analysts recommend KOD or CYTK?

Which has more risk and volatility, KOD or CYTK?

Summary

How does Kodiak Sciences compare to Krystal Biotech?

Is KRYS or KOD more profitable?

Which has higher earnings & valuation, KRYS or KOD?

Which has more risk & volatility, KRYS or KOD?

Do analysts prefer KRYS or KOD?

Do institutionals & insiders have more ownership in KRYS or KOD?

Does the media prefer KRYS or KOD?

Summary

How does Kodiak Sciences compare to Dr. Reddy's Laboratories?

Which has more volatility & risk, KOD or RDY?

Which has stronger earnings and valuation, KOD or RDY?

Do insiders & institutionals hold more shares of KOD or RDY?

Does the media favor KOD or RDY?

Do analysts prefer KOD or RDY?

Is KOD or RDY more profitable?

Summary

How does Kodiak Sciences compare to Nuvalent?

Does the media refer more to KOD or NUVL?

Do institutionals & insiders hold more shares of KOD or NUVL?

Which has more risk & volatility, KOD or NUVL?

Is KOD or NUVL more profitable?

Do analysts prefer KOD or NUVL?

Which has preferable valuation & earnings, KOD or NUVL?

Summary

How does Kodiak Sciences compare to Kymera Therapeutics?

Does the media favor KOD or KYMR?

Do analysts recommend KOD or KYMR?

Which has more risk & volatility, KOD or KYMR?

Do institutionals and insiders hold more shares of KOD or KYMR?

Is KOD or KYMR more profitable?

Which has preferable valuation and earnings, KOD or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools